Status:
UNKNOWN
Clearance Mechanisms in Atypical Neurodegenerative Diseases
Lead Sponsor:
Ludwig-Maximilians - University of Munich
Conditions:
Neurodegenerative Diseases
Frontotemporal Degeneration
Eligibility:
All Genders
50-85 years
Brief Summary
The project PeptiClear aims to investigate whether the blood-brain-barrier (BBB) and the glymphatic system are compromised in atypical neurodegenerative diseases, and whether Alzheimer´s disease (AD)-...
Detailed Description
It is well established for the frequent sporadic (non-genetic) variant of Alzheimer´s disease (AD) that not the overproduction of a specific protein (Amyloid-beta - Aβ) is a major cause but rather the...
Eligibility Criteria
Inclusion
- Diagnosis of Atypical Parkinsonian Disorders or Frontotemporal Dementia
- Able to provide written informed consent
- Unchanged pharmacotherapy within 4 days prior to the study specific assessments
- Fluent in German
Exclusion
- Unable to give informed consent or has a legal guardian
- Other severe mental disorder, e.g. schizophrenia or bipolar affective disorder
- Clinically relevant depression
- Acute suicidality
- Current alcohol, drug or medication abuse
- History of severe traumatic brain injury within 3 months prior to inclusion
- Structural lesions of the basal ganglia or brain stem
- Severe neurological disorder including (but not limited to) epilepsy, systemic disorders, stroke, repeated transient ischaemic attacks, increased brain intracranial pressure, normal pressure hydrocephalus
- Severe medical disorders including (but not limited to) heart failure, respiratory failure, uncontrolled severe arterial hypertension
- Electronic implants (e.g. cardiac pacemaker) or other MRI contraindication
- Renal failure \> stage 3 (GFR \< 30 mL/min)
- Pregnancy
- Unresolved malignancies within two years prior to inclusion
- Severe current infections or other chronic or systemic disorders
- Other circumstances which preclude participation based on the investigator's judgement
Key Trial Info
Start Date :
April 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2024
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT05317871
Start Date
April 1 2022
End Date
April 1 2024
Last Update
March 9 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Klinik und Poliklinik für Psychiatrie und Psychotherapie des LMU Klinikums
München, Bavaria, Germany, 80336